Influence of a nucleotide oligomerization domain 1 (NOD1) polymorphism and NOD2 mutant alleles on Crohn's disease phenotype

Table 5 Clinical characteristics of CD patients according to NOD2 genotype

Clinical features	n1	NOD2 genotype, n (%)					P2OR (95% CI)
		WT/WT	R702W/WT	G908R/WT	L1007fsinsC/WT	Heter.compound & homozygous
Age at diagnosis
< 40 yr (A1 + A2)	80	54 (55.67)3	13 (13.40)	3 (3.09)	4 (4.12)	6 (6.18)	0.57 1.56 (0.46-5.27)
> 40 yr (A3)	17	13 (13.40)	3 (3.09)	0	1 (1.03)	0
Location
Ileal (L1)	34	21 (21.65)	8 (8.25)	1 (1.03)	2 (2.06)	2 (2.06)	0.26 1.67 (0.69-4.06)
Colonic (L2)	23	20 (20.62)	0	1 (1.03)	1 (1.03)	1 (1.03)	0.04 0.26 (0.07-0.96)
Ileocolonic (L3)	40	26 (26.80)	8 (8.25)	1 (1.03)	2 (2.06)	3 (3.09)	0.5 1.38 (0.57-3.29)
Behavior
Non-stricturing, non-penetrating (B1)	37	24 (24.74)	8 (8.25)	3 (3.09)	2 (2.06)	0	0.5 1.37 (0.56-3.29)
Stricturing (B2)	41	34 (35.05)	5 (5.15)	0	0	2 (2.06)	0.01 0.29 (0.11-0.78)
Penetrating (B3)	19	9 (9.28)	3 (3.09)	0	3 (3.09)	4 (4.12)	0.02 3.22 (1.14-9.06)

CD: Crohn's disease; WT: Wildtype. ¹Number of CD patients in each subgroup; ²P-values, odds ratios and confidence intervals refer to the comparison of presence versus absence of the at least one mutant NOD2 allele;

³Results are expressed as number of CD patients (% of CD patients).